1.1Fibronectin loop recognition
Three exposed loops on the beta sandwich carry side chains selected for binding the tag peptide. Basic residues contact tag aspartates, and a hydrophobic pocket accommodates its tyrosine side chain.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Three exposed loops on the beta sandwich carry side chains selected for binding the tag peptide. Basic residues contact tag aspartates, and a hydrophobic pocket accommodates its tyrosine side chain.
A single-domain antibody presents three recognition loops on one folded domain. Selection against immobilized tag peptide enriches domains whose loops bind the exposed tag on a fusion protein.
Three internal ankyrin repeats present variable surface residues along a continuous concave face. Selection against the tag peptide identifies repeat proteins whose side chains contact multiple positions along the peptide.
A flexible peptide linker joins two light-chain variable domains that pack as a dimer. Selection against the tag peptide identifies dimers whose adjacent loops form a shared binding surface.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A synthetic fluorescent tracer bearing the DYKDDDDK peptide coats a test article that passes through a packaging line during setup. Swabs collect material from guides, rollers, and other contact surfaces after the run. An immobilized antibody with paired heavy- and light-chain variable domains captures the tracer from each swab extract through its peptide tag. Fluorescence measurements against a tracer dilution series quantify transfer at each sampling point.
A single-domain antibody selected for binding to DYKDDDDK replaces the paired heavy- and light-chain binding domain. A terminal cysteine positioned away from the binding surface couples the single-domain antibody to maleimide-functionalized magnetic beads. The beads capture tagged proteins during mixing, and a magnet holds the beads in place during washing. Soluble DYKDDDDK competes for the binding sites and releases the captured proteins.
A 384-well plate holds 20 microliters of sample and 2 microliters of a 10 milligram per milliliter suspension of magnetic beads coated with antibody against DYKDDDDK in each well. The plate mixes for 15 minutes at room temperature before a magnetic plate base collects the beads. Each well receives three 30-microliter washes followed by 10 microliters of elution buffer containing 0.5 milligrams per milliliter of soluble DYKDDDDK. After 10 minutes, the magnetic base holds the beads while the eluates transfer to a separate plate.
A synthetic calibration scaffold displays two copies of DYKDDDDK connected through separate flexible spacers. Three scaffold variants place the spacer attachment points 5, 10, or 20 nanometers apart. Each variant anchors to a sensor surface through a single attachment point, and an intact antibody with two identical tag-binding sites passes over the surface. The sensor records association and dissociation at each spacing to measure how tag separation changes antibody retention.
A switching valve connects a cartridge containing immobilized antibody against DYKDDDDK to a liquid chromatography system with a mass spectrometer. The loading stream passes through the cartridge, which retains tagged proteins while unbound material flows to waste. A low-pH pulse releases the retained proteins onto a reversed-phase trap, which concentrates them and washes away salts. A solvent gradient transfers the proteins to the analytical column for separation and intact mass measurement.
Two columns containing immobilized antibody against DYKDDDDK connect to a feed pump through a motorized switching valve. Software periodically diverts a sample of the active column's outlet into a fluorescence assay that uses a second anti-tag antibody as a tracer and measures tag concentration by fluorescence polarization. When the measured outlet concentration exceeds five percent of the feed concentration in two consecutive readings, the controller switches the feed to the second column. A separate pump washes, elutes, and re-equilibrates the first column while the second column loads.
A heavy-chain variable domain and a light-chain variable domain from the listed sets join through a 15-residue glycine-serine linker. The linked domains pair within one polypeptide and bring their six recognition loops together at the peptide binding surface.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
An isolated antibody or antigen-binding fragment thereof, which specifically binds human interleukin-4 receptor (hIL-4R) comprising the amino acid sequence of SEQ ID NO: 1, comprising a heavy chain variable region comprising three heavy-chain CDRs, and a light chain variable region comprising three light-chain CDRs, wherein said three heavy-chain CDRs comprise the CDR1, CDR2 and CDR3 from SEQ ID NO:581, and said three light-chain CDRs comprise the CDR1, CDR2 and CDR3 from SEQA · US 7,605,237 B2 · claim 1
Another embodiment of the invention relates to an antigen binding protein, or an antigen binding fragment thereof, comprising a light chain variable domain of sequence SEQ ID NO. 7, or any sequence exhibiting at least 80%, preferably 85%, 90%, 95% and 98% identity with SEQ ID NO. 7; and the three heavy chain CDRs comprising the sequences SEQ ID NOs. 4, 5 and 6, or any sequence exhibiting at least 80%, preferably 85%, 90%, 95% and 98% identity with SEQ ID NOs. 4, 5 and 6.B · US 2016/0046725 A1 · ¶ 114
An empty cell means only that no passage was reproduced there.
The human antibodies are characterized by binding to hIL-4R with high affinity and by the ability to neutralize hIL-4 activity.A · US 7,605,237 B2 · ¶ 6
In specific embodiments, the human antibodies are capable of blocking hIL-13/hIL-13R1 complex binding to hIL-4R, and thus inhibit signaling by hIL-13.A · US 7,605,237 B2 · ¶ 6
From one aspect, the invention relates to novel antigen binding proteins, or antigen binding fragments, capable of binding to Axl and, by inducing internalization of Axl, being internalized into the cell.B · US 2016/0046725 A1 · ¶ 1
The invention also comprises the use of said antigen binding proteins as addressing products in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.B · US 2016/0046725 A1 · ¶ 1
patent.fyi, US 2026/0356982 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356982/, SHA-256 fa7f296d9060e4a71d867d5407fb3ceb3a74556bdfb5c6164ef65ece05d77f4e